Biogen, in Reversal, Will Seek FDA OK for Alzheimer’s Drug After Further Analysis

Change in plans follows an analysis of a larger dataset from studies of aducanumab; share price surges on the newsBiogen Inc. said it plans to pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer’s disease, after pulling the plug on phase 3 studies of the drug earlier this year.

Shares of Biogen surged 40% in premarket trading, putting the company on track to add more than $16 billion in market value. When the company and partner Eisai & Co. in March said they would terminate the late-stage studies, Biogen lost about $18 billion in market value.

no medical innovations out of China? didn't think so. Trump2020

We shudder to think of this drug's monthly price tag should it be approved for the market and who is going to pay for it.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA OKs Diabetes Drug for Type 2 Heart Failure RiskThe FDA granted a new use for diabetes drug Farxiga (dapagliflozin): to reduce the risk of hospitalization for heart failure in adults who have type 2 diabetes and established heart disease or risk factors for it. The cost will be $5000
Source: WebMD - 🏆 709. / 51 Read more »